Healthcare Biz Cheat Sheet: Novavax Wins $1.3M Government Contract; Forest Labs, BioCryst Drugs Get Results
Novavax (NASDAQ:NVAX) is trading higher after winning a $1.3 million contract from the U.S. Department of Homeland Security to develop a virus-like particle vaccine to protect against foot-and-mouth disease.
Hot Feature: Is the 2008 Bear Market Back?
BioCryst Pharmaceuticals (NASDAQ:BCRX) has announced positive-top line results for a Phase 2 study of its gout treatment, meeting its goal for the drug.
Forest Laboratories (NYSE:FRX) says preliminary results from a clinical trial of its experimental anti-psychotic drug Cariprazine showed improvement of bipolar mania symptoms compared to a placebo.